PT  - JOURNAL ARTICLE
AU  - Li, Ping
AU  - Liu, Yang
AU  - Liang, Yun
AU  - Bo, Jian
AU  - Gao, Sujun
AU  - Hu, Yongxian
AU  - Hu, Yu
AU  - Huang, He
AU  - Huang, Xiaojun
AU  - Jing, Hongmei
AU  - Ke, Xiaoyan
AU  - Li, Jianyong
AU  - Li, Yuhua
AU  - Liu, Qifa
AU  - Lu, Peihua
AU  - Mei, Heng
AU  - Niu, Ting
AU  - Song, Yongping
AU  - Song, Yuqin
AU  - Su, Liping
AU  - Tu, Sanfang
AU  - Wang, Jianxiang
AU  - Wu, Depei
AU  - Wang, Zhao
AU  - Xu, Kailin
AU  - Ying, Zhitao
AU  - Yang, Qingming
AU  - Zhang, Yajing
AU  - Shi, Fengxia
AU  - Zhang, Bin
AU  - Zhang, Huilai
AU  - Zhang, Xi
AU  - Zhao, Mingfeng
AU  - Zhao, Weili
AU  - Zhao, Xiangyu
AU  - Huang, Liang
AU  - Zhu, Jun
AU  - Qian, Wenbin
AU  - Han, Weidong
AU  - Liang, Aibin
TI  - 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
AID  - 10.20892/j.issn.2095-3941.2022.0585
DP  - 2023 Feb 15
TA  - Cancer Biology & Medicine
PG  - 129--146
VI  - 20
IP  - 2
4099  - http://www.cancerbiomed.org/content/20/2/129.short
4100  - http://www.cancerbiomed.org/content/20/2/129.full
SO  - Cancer Biology & Medicine2023 Feb 15; 20
AB  - Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cells has emerged as a novel modality for treating relapsed and/or refractory B-cell non-Hodgkin lymphoma (B-NHL). With increasing approval of CAR T-cell products and advances in CAR T cell therapy, CAR T cells are expected to be used in a growing number of cases. However, CAR T-cell-associated toxicities can be severe or even fatal, thus compromising the survival benefit from this therapy. Standardizing and studying the clinical management of these toxicities are imperative. In contrast to other hematological malignancies, such as acute lymphoblastic leukemia and multiple myeloma, anti-CD19 CAR T-cell-associated toxicities in B-NHL have several distinctive features, most notably local cytokine-release syndrome (CRS). However, previously published guidelines have provided few specific recommendations for the grading and management of toxicities associated with CAR T-cell treatment for B-NHL. Consequently, we developed this consensus for the prevention, recognition, and management of these toxicities, on the basis of published literature regarding the management of anti-CD19 CAR T-cell-associated toxicities and the clinical experience of multiple Chinese institutions. This consensus refines a grading system and classification of CRS in B-NHL and corresponding measures for CRS management, and delineates comprehensive principles and exploratory recommendations for managing anti-CD19 CAR T-cell-associated toxicities in addition to CRS.